pharmaphorum August 26, 2024
Siemens Healthineers has agreed a €200 million ($224 million) deal to buy the diagnostic arm of Novartis’ Advanced Accelerator Applications (AAA) radiopharma unit, boosting its medical imaging business.
The deal – originally reported by the Financial Times and confirmed by Novartis and Siemens Healthineers over the weekend without giving the value of the transaction – would leave Novartis holding only the radiotherapeutics operations of AAA, which it bought for $3.9 billion in 2017 to underpin its move into the radiopharma category.
The Swiss pharma group said it would continue to work with Siemens Healthineers to support and supply its radioligand therapies (RLTs), which include Lutathera (lutetium [Lu177] dotatate) for GEP-NET tumours, prostate cancer treatment Pluvicto (lutetium [Lu177] vipivotide tetraxetan), and...
Today's Sponsors
Today's Sponsor